Innoviva, Inc. — fact timeline

Josephine Linden was elected as Director at Innoviva, Inc..

“On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the “Linden Effective Date”).”

Mark DiPaolo resigned as Director at Innoviva, Inc..

“On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.”

Derek Small resigned as Director at Innoviva, Inc..

“On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.”

Innoviva, Inc. reported first quarter ended March 31, 2026 results: revenue $98.0 million, net income $186.6 million, EPS $2.52 basic earnings per share.

“and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld. Financial Highlights for the First Quarter of 2026 • Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. • Royalty revenue: gross royalty revenue from Glaxo Group Limited (“GSK”) was $58.6 million, compared”

Innoviva, Inc. shareholders approved Approval of 2026 Equity Incentive Plan at the 2026-05-04 meeting.

“At the Meeting, our stockholders also approved Innoviva’s 2026 Equity Incentive Plan. The vote for such approval was 55,435,111 shares for, 3,766,788 shares against, 36,028 shares abstaining, and 6,809,010 shares of broker non-votes.”

Innoviva, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-05-04 meeting.

“Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 66,008,453 shares for, 16,574 shares against, 21,910 shares abstaining and 0 broker non-votes.”

Innoviva, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-04 meeting.

“At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 56,243,880 shares for, 2,836,001 shares against, 158,046 shares abstaining, and 6,809,010 shares of broker non-votes.”

Innoviva, Inc. shareholders approved Election of five directors at the 2026-05-04 meeting.

“At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non-Votes Derek Small 56,752,327 2,485,600 6,809,010 Mark A. DiPaolo, Esq. 50,072,119 9,165,808 6,809,010 Jules Haimovitz 56,834,625 2,403,302 6,809,010 Sarah J. Schlesinger, M.D. 53,509,479 5,728,448 6,809,010 Pavel Raifeld 58,880,013 357,914 6,809,010”

Innoviva, Inc. reported first quarter ended March 31, 2024 results: net income $36.5 million, or $0.58 basic per share.

“Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024.”

Derek Small was appointed as Director at Innoviva, Inc..

“On and effective as of April 29, 2024 (the “Small Effective Date”), Innoviva, Inc. (the “Company”) appointed Derek Small, to its Board of Directors (the “Board”).”

Innoviva, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net income was $61.5 million, or $0.97 basic per share.

“On February 29, 2024, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023.”

Innoviva, Inc. reported the third quarter ended September 30, 2023 results: net income $82.0 million, EPS $1.26 basic per share.

“On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.”

Stephen Basso was appointed as Chief Financial Officer at Innoviva, Inc..

“On August 25, 2023, Innoviva, Inc. (the “Company”) announced the hiring and appointment of Stephen Basso, age 57, Chief Financial Officer of the Company, effective as of August 21, 2023.”

Innoviva, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(a)(2), 5605(c)(4)).

“August 2, 2023, Innoviva, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, due to Dr. Deborah L. Birx’s previously disclosed resignation from the Company’s Board of Directors (the “Board”), the Company is not in compliance with Nasdaq’s audit committee composition requirements, as set forth in Nasdaq Listing Rule 5605, which requires that the Audit Committee of the Board (the “Audit Committee”) be comprised of at least three “independent directors” (as defined in Nasdaq Listing”

Innoviva, Inc. reported the second quarter ended June 30, 2023 results: net income $1.3 million, or $0.02 basic per share, EPS $0.02 basic per share.

“Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2023.”

Deborah L. Birx resigned as member of the Board of Directors and chair of the Audit Committee at Innoviva, Inc..

“On July 10, 2023, Deborah L. Birx, a member of the Board of Directors of Innoviva, Inc. (the “Board”) and chair of the Audit Committee, resigned from the Board, including the committees of the Board of which she is a member, effective as of July 10, 2023”

Innoviva, Inc. shareholders approved Approval of Innoviva, Inc. 2023 Employee Stock Purchase Plan at the 2023-05-22 meeting.

“Also at the Meeting, our stockholders next approved the Innoviva, Inc. 2023 Employee Stock Purchase Plan. The vote for such approval was 54,298,015 shares for, 130,716 shares against, 70,349 shares abstaining and 4,319,019 broker non-votes.”

Innoviva, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2023 at the 2023-05-22 meeting.

“Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote for such ratification was 58,801,428 shares for, 11,607 shares against, 5,064 shares abstaining and no broker non-votes.”

Innoviva, Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes (one year) at the 2023-05-22 meeting.

“Also at the Meeting, our stockholders next approved one year as the frequency of non-binding advisory votes on Innoviva’s executive compensation. The vote for such approval was 51,448,996 shares for one year, 19,063 shares for two years, 2,986,237 shares for three years, 44,784 shares abstaining and 4,319,019 broker non-votes.”

Innoviva, Inc. shareholders approved Advisory vote to approve executive compensation at the 2023-05-22 meeting.

“At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 51,955,275 shares for, 2,512,795 shares against, 31,010 shares abstaining, and 4,319,019 shares of broker non-votes.”

Innoviva, Inc. shareholders approved Election of six directors to serve until the 2024 annual meeting at the 2023-05-22 meeting.

“At the Annual Meeting of Stockholders held on May 22, 2023 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected six members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2024, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non- Votes Deborah L. Birx, M.D. 53,617,426 881,654 4,319,019 Mark DiPaolo, Esq. 54,180,081 318,999 4,319,019 Jules Haimovitz 53,447,741 1,051,339 4,319,019 Odysseas D. Kostas, M.D. 54,168,478 330,602 4,319,019 Sarah Schlesinger, M.D. 52,929,318 1,569,762 4,319,019 Sapna Srivastava, Ph.D. 32,608,554 21,890,526 4,319,019”

Innoviva, Inc. reported first quarter ended March 31, 2023 results: net income Net income was $34.9 million, EPS $0.51 basic per share.

“Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.”

George Bickerstaff, III departed as Chairman of the Board at Innoviva, Inc..

“George Bickerstaff, III, Chairman of the Board, notified the Board of Directors (the “Board”) of Innoviva, Inc. that he will retire from the Board, including the committees of the Board of the Company of which he is a member, at the end of his current term at the 2023 Annual Meeting of shareholders.”

Innoviva, Inc. reported financial results for the fourth quarter ended December 31, 2022.

“On February 28, 2023, Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2022.”

Innoviva, Inc.: Amended the Company's by-laws to remove reference to SmithKline Beecham Corporation as a shareholder and update procedures and information requirements for director nominations, including with respect to Rule 14a-19 (effective 2023-01-01).

“On December 31, 2022, the Board amended the Company’s by-laws, effective as of January 1, 2023, to remove reference to SmithKline Beecham Corporation, a Pennsylvania corporation, as a shareholder of the Company and update the procedures and information requirements for the nomination of directors, including with respect to Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended.”

Sapna Srivastava was appointed as Director at Innoviva, Inc..

“On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).”

Innoviva, Inc. completed a disposition involving Royalty Pharma Investments 2019 ICAV for an upfront cash payment of $281.9 million and a $50 million contingent sales-based milestone payment (closed 2022-07-20).

“On July 20, 2022, Innoviva TRC Holdings LLC (the “Seller”), a Delaware limited liability company and wholly-owned subsidiary of Innoviva, Inc. (the “Company”), completed the sale (the “Sale”) contemplated by the Equity Purchase Agreement (the “Purchase Agreement”) dated July 13, 2022, by and among the Company, the Seller and Royalty Pharma Investments 2019 ICAV (the “Buyer”), pursuant to which Seller agreed to sell its 750 Class A Units and 750 Class C Units of Theravance Respiratory Company, LLC (“TRC”) (the “Seller Equity”), representing all of the Seller’s 15% ownership in TRC, to the Buyer for an upfront cash payment of $281.9 million and a $50 million contingent sales-based milestone payment, on the terms and conditions set forth in the Purchase Agreement.”